2 Stocks Up Over 600% in the Past 3 Years With More Room to Run

Summit Therapeutics has an incredibly promising cancer candidate in the pipeline. Madrigal Pharmaceuticals made a breakthrough that could drive strong results for years to come.

The Motley Fool • Dec 9, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on December 1, 2025 to 24 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Dec 4, 2025

Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue?

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 4, 2025

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Madrigal Pharmaceuticals, Inc. ( MDGL ) Jefferies London Healthcare Conference 2025 November 20, 2025 3:30 AM EST Company Participants William Sibold - CEO, President & Director Mardi Dier - Executive VP & CFO David Soergel - Executive VP & Chief Medical Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Good morning, everyone. We've made it to our last day of our London Healthcare Conference.

Seeking Alpha • Nov 20, 2025

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:

GlobeNewsWire • Nov 17, 2025

Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis

Rezdiffra ® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra also improved disease-specific quality of life measures in patients with and without cirrhosis, with sustained effect through two years of treatment New analysis examining effects of Rezdiffra treatment interruption underscores the need for sustained therapy to prevent disease progression CONSHOHOCKEN, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced positive two-year data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial, evaluating the use of Rezdiffra in an advanced, difficult-to-treat patient population with no approved therapies.

GlobeNewsWire • Nov 10, 2025

Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up

MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.

Zacks Investment Research • Nov 5, 2025

Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call Transcript

Madrigal Pharmaceuticals, Inc. ( MDGL ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Tina Ventura - Chief Investor Relations Officer William Sibold - CEO, President & Director David Soergel - Executive VP & Chief Medical Officer Mardi Dier - Executive VP & CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co., Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Akash Tewari - Jefferies LLC, Research Division Thomas Smith - Leerink Partners LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Ritu Baral - TD Cowen, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Kaveri Pohlman - Clear Street LLC Presentation Operator Good morning, and thank you for standing by. Welcome to the Madrigal Pharmaceuticals Third Quarter 2025 Earnings Conference Call.

Seeking Alpha • Nov 4, 2025

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

Third -quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 million As of September 30, 2025 , more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion as of Sept. 30, 2025 Company to host conference call today, Nov. 4, 2025, at 8 a.m.

GlobeNewsWire • Nov 4, 2025

Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates

Madrigal (MDGL) came out with a quarterly loss of $5.08 per share versus the Zacks Consensus Estimate of a loss of $1.98. This compares to a loss of $4.92 per share a year ago.

Zacks Investment Research • Nov 4, 2025